Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT05620836 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT05620836
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05620836 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa
Lead sponsor
Incyte Corporation
Phase
Phase 3
Overall status
Completed
Start date
February 22, 2023
Completion date
November 21, 2025
Enrollment
619 (actual)
Sites
101

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa (hs)